Date: 25th September, 2018

Time: 12 – 2 pm (Lunch provided)

Venue: Large Seminar Room, First floor, Institute of Public Health,

Addenbrookes Site, University of Cambridge, CB2 0SR

This seminar by Prof. Peter Weissberg will cover - Key criteria for research translatability that should guide development of a new therapeutics strategy as well as achieve commercial proposition for attracting investments. These criteria include consideration of product differentiation, target validation, risk reduction and proof-of-concept clinical trial design. To illustrate these points Peter will refer to case-studies, such as X01 Ltd., a Cambridge based company. The seminar will also provide an opportunity to discuss particular issues relating to your own research with Prof Weissberg.

About the speaker: Prof. Peter Weissberg is currently an investment advisor for Medicxi, a leading life sciences-focused venture capital firm, having recently stepped down from his role as Medical Director of the British Heart Foundation. Prior to that he was the BHF Professor of Cardiovascular Medicine in the University of Cambridge and Consultant Cardiologist at Addenbrooke’s Hospital. He is a fellow of Wolfson College Cambridge, the Academy of Medical Sciences and the Royal College of Physicians and currently chairs UK Bio Centre and the Research Council of the Scar Free Foundation. In 2017, he was appointed CBE for services to medical research and cardiovascular health.

Please register here to attend the event, as seats are limited.

Developing a new drug - the pathway towards successful translation